172 related articles for article (PubMed ID: 23823853)
21. Cancer-associated fibroblasts confer cisplatin resistance of tongue cancer via autophagy activation.
Liao JK; Zhou B; Zhuang XM; Zhuang PL; Zhang DM; Chen WL
Biomed Pharmacother; 2018 Jan; 97():1341-1348. PubMed ID: 29156523
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of Autophagy Potentiated the Antitumor Effect of Nedaplatin in Cisplatin-Resistant Nasopharyngeal Carcinoma Cells.
Liu Z; Liu J; Li L; Nie D; Tao Q; Wu J; Fan J; Lin C; Zhao S; Ju D
PLoS One; 2015; 10(8):e0135236. PubMed ID: 26288183
[TBL] [Abstract][Full Text] [Related]
23. eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma.
Liu T; Li R; Zhao H; Deng J; Long Y; Shuai MT; Li Q; Gu H; Chen YQ; Leng AM
Oncotarget; 2016 Oct; 7(41):66851-66864. PubMed ID: 27588477
[TBL] [Abstract][Full Text] [Related]
24. HAX-1 promotes the chemoresistance, invasion, and tumorigenicity of esophageal squamous carcinoma cells.
Sun SJ; Feng L; Zhao GQ; Dong ZM
Dig Dis Sci; 2012 Jul; 57(7):1838-46. PubMed ID: 22451114
[TBL] [Abstract][Full Text] [Related]
25. P21-activated kinase 7 mediates cisplatin-resistance of esophageal squamous carcinoma cells with Aurora-A overexpression.
He S; Feng M; Liu M; Yang S; Yan S; Zhang W; Wang Z; Hu C; Xu Q; Chen L; Zhu H; Xu N
PLoS One; 2014; 9(12):e113989. PubMed ID: 25436453
[TBL] [Abstract][Full Text] [Related]
26. Role of autophagy in the resistance to tumour necrosis factor-related apoptosis-inducing ligand-induced apoptosis in papillary and anaplastic thyroid cancer cells.
Jin SM; Jang HW; Sohn SY; Kim NK; Joung JY; Cho YY; Kim SW; Chung JH
Endocrine; 2014 Mar; 45(2):256-62. PubMed ID: 23821365
[TBL] [Abstract][Full Text] [Related]
27. 14-3-3σ confers cisplatin resistance in esophageal squamous cell carcinoma cells via regulating DNA repair molecules.
Lai KK; Chan KT; Choi MY; Wang HK; Fung EY; Lam HY; Tan W; Tung LN; Tong DK; Sun RW; Lee NP; Law S
Tumour Biol; 2016 Feb; 37(2):2127-36. PubMed ID: 26346170
[TBL] [Abstract][Full Text] [Related]
28. Proteasome inhibitor MG132 inhibits the proliferation and promotes the cisplatin-induced apoptosis of human esophageal squamous cell carcinoma cells.
Dang L; Wen F; Yang Y; Liu D; Wu K; Qi Y; Li X; Zhao J; Zhu D; Zhang C; Zhao S
Int J Mol Med; 2014 May; 33(5):1083-8. PubMed ID: 24584782
[TBL] [Abstract][Full Text] [Related]
29. [Effect of intratumor heterogeneity of esophageal squamous cell carcinoma on chemotherapy sensitivity].
Sun L; Wu W; Yan M; Han PL; Zhan X; Ma XW; Cao XG; Zhao S; Gao F; Qi Y; Cao W
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):657-663. PubMed ID: 28926893
[No Abstract] [Full Text] [Related]
30. Autophagy inhibition increased the anti-tumor effect of cisplatin on drug-resistant esophageal cancer cells.
Cheng CY; Liu JC; Wang JJ; Li YH; Pan J; Zhang YR
J Biol Regul Homeost Agents; 2017; 31(3):645-652. PubMed ID: 28954454
[TBL] [Abstract][Full Text] [Related]
31. The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.
Ui T; Morishima K; Saito S; Sakuma Y; Fujii H; Hosoya Y; Ishikawa S; Aburatani H; Fukayama M; Niki T; Yasuda Y
Oncol Rep; 2014 Feb; 31(2):619-24. PubMed ID: 24317439
[TBL] [Abstract][Full Text] [Related]
32. Targeting MCL-1 sensitizes human esophageal squamous cell carcinoma cells to cisplatin-induced apoptosis.
Yu X; Li W; Xia Z; Xie L; Ma X; Liang Q; Liu L; Wang J; Zhou X; Yang Y; Liu H
BMC Cancer; 2017 Jun; 17(1):449. PubMed ID: 28659182
[TBL] [Abstract][Full Text] [Related]
33. Cisplatin induces protective autophagy through activation of BECN1 in human bladder cancer cells.
Lin JF; Lin YC; Tsai TF; Chen HE; Chou KY; Hwang TI
Drug Des Devel Ther; 2017; 11():1517-1533. PubMed ID: 28553083
[TBL] [Abstract][Full Text] [Related]
34.
Hou XF; Xu LP; Song HY; Li S; Wu C; Wang JF
World J Gastroenterol; 2017 Mar; 23(10):1796-1803. PubMed ID: 28348485
[TBL] [Abstract][Full Text] [Related]
35. HNRNPUL1 inhibits cisplatin sensitivity of esophageal squamous cell carcinoma through regulating the formation of circMAN1A2.
Li J; Sang M; Zheng Y; Meng L; Gu L; Li Z; Liu F; Wu Y; Li W; Shan B
Exp Cell Res; 2021 Dec; 409(1):112891. PubMed ID: 34688610
[TBL] [Abstract][Full Text] [Related]
36. Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin.
Wang F; Ding X; Wang T; Shan Z; Wang J; Wu S; Chi Y; Zhang Y; Lv Z; Wang L; Fan Q
PLoS One; 2017; 12(4):e0174276. PubMed ID: 28406985
[TBL] [Abstract][Full Text] [Related]
37. PAX5 gene as a novel methylation marker that predicts both clinical outcome and cisplatin sensitivity in esophageal squamous cell carcinoma.
Kurimoto K; Hayashi M; Guerrero-Preston R; Koike M; Kanda M; Hirabayashi S; Tanabe H; Takano N; Iwata N; Niwa Y; Takami H; Kobayashi D; Tanaka C; Yamada S; Nakayama G; Sugimoto H; Fujii T; Fujiwara M; Kodera Y
Epigenetics; 2017; 12(10):865-874. PubMed ID: 29099287
[TBL] [Abstract][Full Text] [Related]
38. Role of AMPK signaling in mediating the anticancer effects of silibinin in esophageal squamous cell carcinoma.
Li J; Li B; Xu WW; Chan KW; Guan XY; Qin YR; Lee NP; Chan KT; Law S; Tsao SW; Cheung AL
Expert Opin Ther Targets; 2016; 20(1):7-18. PubMed ID: 26568207
[TBL] [Abstract][Full Text] [Related]
39. Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma.
Kondo K; Yamasaki S; Inoue N; Sugie T; Teratani N; Kan T; Shimada Y
Surg Today; 2006; 36(11):966-74. PubMed ID: 17072716
[TBL] [Abstract][Full Text] [Related]
40. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
